An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects

An innovative open-label, crossover clinical study was used to investigate the excretion balance, pharmacokinetics, and metabolism of nemiralisib-an inhaled phosphoinositide 3-kinase delta inhibitor being developed for respiratory diseases. Six healthy men received a single intravenous microtracer o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug metabolism and disposition Jg. 47; H. 12; S. 1457
Hauptverfasser:	Harrell, Andrew W, Wilson, Robert, Man, Yau Lun, Riddell, Kylie, Jarvis, Emily, Young, Graeme, Chambers, Robert, Crossman, Lee, Georgiou, Alex, Pereira, Adrian, Kenworthy, David, Beaumont, Claire, Marotti, Miriam, Wilkes, Denisa, Hessel, Edith M, Fahy, William A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.12.2019
Schlagworte:	Administration, Inhalation Administration, Intravenous Administration, Oral Adult Biological Availability Carbon Radioisotopes Cross-Over Studies Drug Monitoring - methods Feces - chemistry Healthy Volunteers Humans Indazoles - administration & dosage Indazoles - blood Indazoles - pharmacokinetics Indazoles - urine Indoles - administration & dosage Indoles - blood Indoles - pharmacokinetics Indoles - urine Injections, Intravenous Male Metabolic Clearance Rate Middle Aged Oxazoles - administration & dosage Oxazoles - blood Oxazoles - pharmacokinetics Oxazoles - urine Piperazines - administration & dosage Piperazines - blood Piperazines - pharmacokinetics Piperazines - urine Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - blood Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - urine Tissue Distribution
ISSN:	1521-009X, 1521-009X
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!